泌尿生殖系统肿瘤的新型治疗方法：最新进展。
Novel therapies in genitourinary cancer: an update.
机构信息
Department of Medicine, Stony Brook University Medical Center, Stony Brook, New York, USA.
出版信息
J Hematol Oncol. 2008 Aug 11;1:11. doi: 10.1186/1756-8722-1-11.
Abstract
In recent years, new treatment for renal cell carcinoma (RCC) has been a spotlight in the field of cancer therapeutics. With several emerging agents branded as 'targeted therapy' now available, both medical oncologists and urologists are progressively more hopeful for better outcomes. The new remedies may provide patients with improved survival and at the same time less toxicity when compared to traditional cytotoxic agents. This article will center on current and emerging treatment strategies for advanced RCC and other GU malignancies with updates from 2008 annual ASCO meeting.
摘要
近年来，肾细胞癌（RCC）的新治疗方法一直是癌症治疗领域的焦点。随着几种新兴的被称为“靶向治疗”的药物的出现，肿瘤内科医生和泌尿科医生都对更好的治疗效果越来越抱有希望。与传统细胞毒性药物相比，新疗法可能为患者提供更好的生存机会，同时减少毒性。本文将重点介绍 2008 年 ASCO 年会更新的晚期 RCC 和其他 GU 恶性肿瘤的最新治疗策略。
相似文献
1
Novel therapies in genitourinary cancer: an update.泌尿生殖系统肿瘤的新型治疗方法：最新进展。
J Hematol Oncol. 2008 Aug 11;1:11. doi: 10.1186/1756-8722-1-11.
2
Characterization of outcomes in patients with advanced genitourinary malignancies treated with immune checkpoint inhibitors.晚期泌尿生殖系统恶性肿瘤患者接受免疫检查点抑制剂治疗的结局特征。
Urol Oncol. 2021 Jul;39(7):437.e1-437.e9. doi: 10.1016/j.urolonc.2021.01.006. Epub 2021 Jan 23.
3
Novel immunotherapy combinations for genitourinary cancers.新型免疫疗法联合治疗泌尿生殖系统癌症。
Expert Opin Biol Ther. 2020 Mar;20(3):253-262. doi: 10.1080/14712598.2020.1713086. Epub 2020 Jan 27.
4
MET abnormalities in patients with genitourinary malignancies and outcomes with c-MET inhibitors.泌尿生殖系统恶性肿瘤患者的MET异常及c-MET抑制剂的治疗结果。
Clin Genitourin Cancer. 2015 Feb;13(1):e19-26. doi: 10.1016/j.clgc.2014.06.017. Epub 2014 Jul 3.
5
Cabozantinib in genitourinary malignancies.卡博替尼在泌尿生殖系统恶性肿瘤中的应用
Future Oncol. 2017 Apr;13(8):755-765. doi: 10.2217/fon-2016-0358. Epub 2016 Nov 15.
6
New perspectives in advanced genitourinary malignancies.晚期泌尿生殖系统恶性肿瘤的新视角。
Tumori. 2012 Mar-Apr;98(2):267-9. doi: 10.1177/030089161209800215.
7
Immune checkpoint inhibitors in genitourinary malignancies.免疫检查点抑制剂在泌尿生殖系统恶性肿瘤中的应用。
Curr Oncol. 2020 Apr;27(Suppl 2):S69-S77. doi: 10.3747/co.27.5121. Epub 2020 Apr 1.
8
Impact of the incorporation of tyrosine kinase inhibitor agents on the treatment of patients with a diagnosis of advanced renal cell carcinoma: study based on experience at the Hospital Universitario Central de Asturias.酪氨酸激酶抑制剂药物的纳入对诊断为晚期肾细胞癌患者治疗的影响：基于阿斯图里亚斯中央大学医院经验的研究。
Clin Transl Oncol. 2010 Aug;12(8):562-7. doi: 10.1007/s12094-010-0554-0.
9
Genitourinary cancers updates: highlights from ASCO 2023.泌尿生殖系统癌症最新进展：2023 年 ASCO 会议要点。
J Hematol Oncol. 2023 Nov 21;16(1):112. doi: 10.1186/s13045-023-01511-8.
10
American Society of Clinical Oncology 41st annual meeting.美国临床肿瘤学会第41届年会。
Expert Opin Biol Ther. 2005 Aug;5(8):1117-27. doi: 10.1517/14712598.5.8.1117.
本文引用的文献
1
Sunitinib malate for metastatic castration-resistant prostate cancer following docetaxel-based chemotherapy.苹果酸舒尼替尼治疗多西他赛化疗后转移性去势抵抗性前列腺癌
Ann Oncol. 2010 Feb;21(2):319-324. doi: 10.1093/annonc/mdp323. Epub 2009 Jul 24.
2
Phase II study of sunitinib in men with advanced prostate cancer.舒尼替尼用于晚期前列腺癌男性患者的II期研究。
Ann Oncol. 2009 May;20(5):913-20. doi: 10.1093/annonc/mdp111.
3
Randomized phase II trial of first-line treatment with sorafenib versus interferon Alfa-2a in patients with metastatic renal cell carcinoma.索拉非尼与干扰素α-2a一线治疗转移性肾细胞癌患者的随机II期试验。
J Clin Oncol. 2009 Mar 10;27(8):1280-9. doi: 10.1200/JCO.2008.19.3342. Epub 2009 Jan 26.
4
Lenalidomide therapy for metastatic renal cell carcinoma.来那度胺治疗转移性肾细胞癌。
Am J Clin Oncol. 2008 Jun;31(3):244-9. doi: 10.1097/COC.0b013e31815e451f.
5
Phase II study of combination thalidomide/interleukin-2 therapy plus granulocyte macrophage-colony stimulating factor in patients with metastatic renal cell carcinoma.沙利度胺/白细胞介素-2联合治疗加粒细胞巨噬细胞集落刺激因子用于转移性肾细胞癌患者的II期研究
Am J Clin Oncol. 2008 Jun;31(3):237-43. doi: 10.1097/COC.0b013e31815e4505.
6
Sunitinib therapy in renal cell carcinoma.舒尼替尼治疗肾细胞癌。
BJU Int. 2008 Jun;101(11):1339-42. doi: 10.1111/j.1464-410X.2008.07506.x. Epub 2008 Feb 18.
7
Risk of hand-foot skin reaction with sorafenib: a systematic review and meta-analysis.索拉非尼引起手足皮肤反应的风险：一项系统评价和荟萃分析。
Acta Oncol. 2008;47(2):176-86. doi: 10.1080/02841860701765675.
8
A phase II clinical trial of sorafenib in androgen-independent prostate cancer.索拉非尼治疗去势抵抗性前列腺癌的II期临床试验。
Clin Cancer Res. 2008 Jan 1;14(1):209-14. doi: 10.1158/1078-0432.CCR-07-1355.
9
Phase II trial of lenalidomide in patients with metastatic renal cell carcinoma.来那度胺用于转移性肾细胞癌患者的II期试验。
Invest New Drugs. 2008 Jun;26(3):273-6. doi: 10.1007/s10637-007-9107-y. Epub 2007 Dec 27.
10
Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trial.贝伐单抗联合干扰素α-2a治疗转移性肾细胞癌：一项随机、双盲III期试验。
Lancet. 2007 Dec 22;370(9605):2103-11. doi: 10.1016/S0140-6736(07)61904-7.
Zotero 插件